Stay updated on Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial

Sign up to get notified when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    A site-wide notice was added announcing an NIH website transition and explaining that both “Super Intelligence” and “Artificial Intelligence” may appear in NIH content.
    Difference
    1%
    Check dated 2026-10-25T01:27:56.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The footer’s site revision changed from v3.7.1 to v3.7.2 while the page continued to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-18T01:13:05.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The footer’s site revision label advances from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-11T01:48:10.000Z thumbnail image
  4. Check
    35 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error with the header and footer still visible. This replaces the previous study content and signals restricted access to the page.
    Difference
    21%
    Check dated 2026-09-20T00:25:13.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    A new publication citation has been added under Publications, referencing a Blood Neoplasia article on favezelimab plus pembrolizumab in anti-PD-1-refractory classic Hodgkin lymphoma. This addition provides additional literature context for the study record without altering the study's design, eligibility criteria, or reported results.
    Difference
    0.0%
    Check dated 2026-09-12T23:38:10.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    The page now includes NIH grant/contract references for 2023 and 2018, indicating funding sources, and the revision history shows an update to Revision: v3.6.6, replacing v3.6.5.
    Difference
    0.1%
    Check dated 2026-08-29T21:48:54.000Z thumbnail image

Stay in the know with updates to Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.